Alogliptin benzoate for the treatment of type 2 diabetes

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2014-03-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656566.2014.898750PMID 24646052
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea

  2014cited by this paper
• Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus

  2013cited by this paper
• Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

  2013cited by this paper
• Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus

  2013cited by this paper
• Long-Term Effects of Alogliptin Benzoate in Hemodialysis Patients with Diabetes: A 2-year Study

  2013cited by this paper
• Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas

  2013influential reference
• The cost of diabetes in adults in Australia.

  2013cited by this paper
• Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379

  2013cited by this paper
• Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double‐blind, randomized, 1‐year study

  2013influential reference
• Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non- diabetic subjects: a preliminary report

  2013cited by this paper
• Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies

  2013influential reference
• Economic Costs of Diabetes in the U.S. in 2012

  2013cited by this paper
• Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin

  2013cited by this paper
• The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

  2013cited by this paper
• Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors

  2013cited by this paper
• Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

  2013influential reference
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Promoting research for better diabetes care in Asia: Kyoto declaration on diabetes

  2013cited by this paper
• Pharmacology, physiology, and mechanisms of incretin hormone action.

  2013cited by this paper
• Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.

  2013cited by this paper
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study

  2012influential reference
• Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study

  2012cited by this paper
• Challenges in achieving optimal glycemic control in type 2 diabetes patients with declining renal function: The Southeast Asia perspective

  2012cited by this paper
• Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations

  2012cited by this paper
• Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study

  2012influential reference
• Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial

  2012influential reference
• Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs

  2012cited by this paper
• Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

  2012influential reference
• Health‐related quality of life in subjects with and without Type 2 diabetes: pooled analysis of five population‐based surveys in Germany

  2012cited by this paper
• Longer term safety of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta‐analysis

  2012cited by this paper
• Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans

  2012cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cited by this paper
• Dipeptidyl peptidase‐4 inhibitors and prevention of bone fractures: Effects beyond glyemic control

  2012cited by this paper
• Predicting efficacy of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels

  2012cited by this paper
• Dipeptidyl peptidase‐4 inhibitors are effective in Japanese type 2 diabetic patients with sustained endogenous insulin‐secreting capacity, a higher body mass index and insulin resistance

  2012cited by this paper
• Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

  2011influential reference
• Estimation of HbA1c response to sitagliptin by change in glycated albumin level for 2 weeks

  2011cited by this paper
• Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52‐week, randomized, double‐blind, active‐controlled, parallel‐group study

  2011influential reference
• Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis

  2011cited by this paper
• Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label long‐term extension study

  2011influential reference
• DPP‐4 inhibition and islet function

  2011cited by this paper
• Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus

  2011cited by this paper
• Insulin‐secretion capacity in normal glucose tolerance, impaired glucose tolerance, and diabetes in obese and non‐obese Japanese patients

  2011cited by this paper
• Obesity may attenuate the HbA1c‐lowering effect of sitagliptin in Japanese type 2 diabetic patients

  2011cited by this paper
• Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension

  2011influential reference
• Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes

  2011cited by this paper
• Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial

  2011cited by this paper
• Dipeptidyl peptidase‐4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta‐analysis of randomized controlled trials

  2011cited by this paper
• DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice

  2011cited by this paper
• DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes.

  2010cited by this paper
• Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes

  2010influential reference
• Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.

  2010influential reference
• Causes of death in Japanese diabetics: A questionnaire survey of 18,385 diabetics over a 10‐year period

  2010cited by this paper
• GIP and GLP‐1, the two incretin hormones: Similarities and differences

  2010influential reference
• Twelve weeks treatment with the DPP‐4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non‐glucose induced insulin secretion in patients with type 2 diabetes mellitus

  2010cited by this paper
• Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

  2010cited by this paper
• Little enhancement of meal‐induced glucagon‐like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls

  2010cited by this paper
• Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia

  2009influential reference
• Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies

  2009influential reference
• Efficacy and safety of adding the dipeptidyl peptidase‐4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double‐blind, placebo‐controlled study

  2009influential reference
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

  2009influential reference
• A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.

  2009cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

  2009cited by this paper
• Coadministration of Pioglitazone or Glyburide and Alogliptin: Pharmacokinetic Drug Interaction Assessment in Healthy Participants

  2009cited by this paper
• Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.

  2008influential reference
• Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.

  2008influential reference
• AMH (Australian Medicines Handbook, 2007 Edition)

  2008cited by this paper
• Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.

  2008cited by this paper
• Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.

  2008influential reference
• Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control

  2008cited by this paper
• Postmenopausal Hormone Therapy for Disease Prevention: Have We Learned Any Lessons from the Past?

  2008cited by this paper
• beta-cell failure in diabetes and preservation by clinical treatment.

  2007cited by this paper
• Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.

  2007cited by this paper
• Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes

  2006cited by this paper
• Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes.

  2004cited by this paper
• Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

  1999cited by this paper
• Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49)

  1999cited by this paper
• Drug, Healthcare and Patient Safety Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dipeptidyl Peptidase-4 Inhibitors in the Management of Type 2 Diabetes: Safety, Tolerability, and Efficacy

  year unknowncited by this paper

• In silico ADME and target prediction studies of Alogliptin as drug molecule

  2024cites this paper
• Effects of dulaglutide and trelagliptin on beta-cell function in patients with type 2 diabetes: a randomized controlled study: DUET-beta study

  2024cites this paper
• An Analysis on the UV-Visible Spectrophotometry Method

  2023cites this paper
• Simultaneous Determination of Alogliptin, Linagliptin, Saxagliptin, and Sitagliptin in Bulk Drug and Formulation by UPLC Q-TOF-MS

  2020cites this paper
• PHARMACEUTICAL JOURNAL OF INDONESIA

  2019cites this paper
• Effectiveness And Side Effects Of Alogliptin In Type 2 Diabetes Mellitus Patients.

  2019cites this paper
• EVALUATION OF ANTI DIABETIC DRUG ALOGLIPTIN FOR THE TREATMENT OF OBESITY IN RATS

  2018cites this paper
• EVALUATION OF ANTIDIABETIC DRUG ALOGLIPTIN FOR THE TREATMENT OF INFLAMMATION IN RATS

  2018cites this paper
• Physicochemical characterization of dipeptidyl peptidase-4 inhibitor alogliptin in physical mixtures with excipients

  2017cites this paper
• Solicitud de pruebas de función tiroidea desde Atención Primaria en España

  2016cites this paper
• Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation

  2016influential citation
• Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes

  2015cites this paper
• Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes

  2015cites this paper
• An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus

  2015cites this paper
• DPP-4 inhibitors: focus on safety

  2015cites this paper
• A Comparative Study for the Effect of Rosiglitazone and Sitagliptin on the Myocardium of Diabetic Experimental Animals

  2015cites this paper
• Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus

  2015cites this paper
• Dipeptidyl‐Peptidase‐4 Inhibitor, Alogliptin, Attenuates Arterial Inflammation and Neointimal Formation After Injury in Low‐Density Lipoprotein (LDL) Receptor‐Deficient Mice

  2015cites this paper
• Analyzing the Factors Contributing to Withdrawal from Insulin Therapy Following Additional Administration of Alogliptin: Retrospective Study after Removing Glucotoxicity with Insulin

  2015cites this paper
• Alogliptin benzoate for management of type 2 diabetes

  2015cites this paper
• Incretin-based therapies in prediabetes: Current evidence and future perspectives.

  2014cites this paper
• New and Future Medications for the Treatment of Type 2 Diabetes Mellitus

  2014cites this paper
• Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase

  2014cites this paper
• Alogliptin: Concern About Hepatotoxicity?

  2014cites this paper
• Linagliptin for the treatment of Type 2 diabetes

  2014cites this paper
• Correction: Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms

  2013cites this paper
• Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

  2013cites this paper
• Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin

  2013cites this paper
• Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms

  2013cites this paper
• Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes

  2013cites this paper
• Cardiovascular effects of DPP-4 inhibitors : from risk factors to clinical outcomes

  2013cites this paper
• Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies

  2013cites this paper
• Incretin for the continuing treatment of secondary failure to metformin in Type 2 diabetes

  2013cites this paper
• Treating the obese diabetic

  2013cites this paper
• Differential effects on metabolic parameters between sitagliptin and alogliptin in drug naïve subjects with type 2 diabetes

  2012cites this paper
• Vascular Health and Risk Management Dovepress Alogliptin Benzoate for Management of Type 2 Diabetes

  year unknowncites this paper